← Leaderboard
VRTX
Ticker
VRTX
Congressional Trades
19
by 7 members
Buys
7
37%
Sells
12
63%
Total Volume
$250K
midpoint
Unique Traders
7
members
Party Breakdown
Democrats1 · 5%
Republicans18 · 95%
Party Trading Divergence
Democrat vs. Republican buy / sell pressure by monthMODERATEBar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.
Democrat ←
Month
→ Republican
—
Oct '22
1▲
—
May '24
0▲2▼
—
Oct '24
1▲
—
Dec '24
1▲
—
Feb '25
1▲
—
Mar '25
1▲1▼
—
May '25
0▲2▼
—
Jun '25
0▲4▼
—
Aug '25
2▲
—
Jan '26
0▲2▼
Democrats0▲0▼Neutral
vs
Republicans7▲11▼Net sellers
Net buyingNet selling⚡ Party split
💼 Lobbying Filings
all →- 2026-04-20$80KVERTEX PHARMACEUTICALS INCORPORATEDFederal budget issues Alternatives to PAIN Act, IRA, innovation, health disparities, orphan drugs, drug pricing in federal programs, opioid alternative medicines, awareness of rare kidney disorders Medicare & Medicaid payment and coverage issues
- 2026-04-20$80KVERTEX PHARMACEUTICALS INCORPORATEDAccess to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
- 2026-04-20$60KVERTEX PHARMACEUTICALS INCORPORATEDMonitor issues related to 340b; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC) H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process
- 2026-04-20$50KVERTEX PHARMACEUTICALS INCORPORATEDPatient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
- 2026-04-20$30KVERTEX PHARMACEUTICALS INCORPORATEDGeneral education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
- 2026-04-20$20KVERTEX PHARMACEUTICALS INCORPORATEDFY2027 Appropriations bills. FY2027 Appropriations bills.
- 2026-04-20$0VERTEX PHARMACEUTICALS INCORPORATED
- 2026-04-19$60KTIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS)
- 2026-04-19$60KVERTEX PHARMACEUTICALSIssues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act. Issues related to coverage of opioid alternatives.
- 2026-04-18$50KVERTEX PHARMACEUTICALS INCORPORATEDHR 1227, Alternatives to PAIN Act.
Congressional Momentum
buy vs. sell pressureDISTRIBUTINGScore 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.
Last 30 Days
No trades
Last 90 Days
No trades
All-Time
▼42
7 buys19 total12 sells
$105K buys · $145K sells
Cumulative Net Position (buy vol − sell vol)
-$40K
2019-0219 trades plotted2026-01
Trade Activity Timeline
Congressional buys & sells by month · last 11 months w/ activity
19/02
22/10
24/05
24/10
24/12
25/02
25/03
25/05
25/06
25/08
26/01
BuysSellsOtherHigh-volume month
Who Moved First
each row = one member · sorted by earliest disclosed trade5 buyers ·6 sellers
BuySellOtherDot size ∝ trade size · top 7 most-active traders shown
All Disclosed Trades
| Date | Member | Action | Amount | Filing Delay |
|---|---|---|---|---|
| 2026-01-29 | RDavid Taylor | SELL | $1K – $15K | 5d |
| 2026-01-29 | RDavid Taylor | SELL | $1K – $15K | 4d |
| 2024-10-23 | RJulia Letlow | BUY | $1K – $15K | 447d |
| 2025-08-07 | RDavid Taylor | BUY | $1K – $15K | 27d |
| 2025-08-07 | RDavid Taylor | BUY | $1K – $15K | 26d |
| 2025-06-11 | RLisa McClain | SELL | $1K – $15K | 64d |
| 2025-06-10 | RLisa McClain | SELL | $1K – $15K | 65d |
| 2025-06-11 | RLisa McClain | SELL | $1K – $15K | 63d |
| 2025-06-10 | RLisa McClain | SELL | $1K – $15K | 64d |
| 2024-12-11 | RLisa McClain | BUY | $1K – $15K | 245d |
| 2025-05-12 | RJefferson Shreve | SELL | $15K – $50K | 42d |
| 2025-05-12 | RJefferson Shreve | SELL | $15K – $50K | 41d |
| 2025-03-20 | RByron Donalds | SELL | $1K – $15K | 25d |
| 2025-03-13 | RJefferson Shreve | BUY | $15K – $50K | 29d |
| 2025-02-24 | RJefferson Shreve | BUY | $15K – $50K | 13d |
| 2024-05-03 | RTommy Tuberville | SELL | $1K – $15K | 42d |
| 2024-05-03 | RTommy Tuberville | SELL | $1K – $15K | 42d |
| 2022-10-06 | RTommy Tuberville | BUY | $1K – $15K | 326d |
| 2019-02-04 | DJohn Reed | SELL | $1K – $15K | 1666d |